Inovio Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Inovio Pharmaceuticals (INO).

Price Target Range — 10 Quarters

Analyst Consensus — 8 Analysts

2S.Buy

4Buy

2Hold

Consensus RatingMarket Outperform# Analysts8Avg. Consensus PT$14Upside to Avg. PT+1416.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Jefferies	Roger Song	Upgrade	Hold→Buy	$2→$3
Aug 3, 2026	Piper Sandler	Edward Tenthoff	PT Cut	Overweight	$6→$4
Jun 1, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$3→$3
Nov 14, 2025	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$5→$6
Aug 14, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$3
Jul 9, 2025	Piper Sandler	Edward Tenthoff	Initiate	Overweight	$5
May 14, 2025	RBC Capital	Gregory Renza	Maintained	Sector Perform	$5
May 14, 2025	Oppenheimer	Jay Olson	PT Cut	Outperform	$15→$13
Mar 19, 2025	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$6→$5
Mar 19, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$3
Mar 14, 2025	Citizens Capital Markets	Roy Buchanan	Maintained	Market Outperform	$18
Jan 13, 2025	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$5→$3
Jan 10, 2025	JMP Securities	Roy Buchanan	Maintained	Market Outperform	$18
Nov 18, 2024	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Neutral	$12→$5
Nov 18, 2024	Oppenheimer	Jay Olson	PT Cut	Outperform	$33→$15
Nov 15, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$7→$6
Oct 4, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$8→$7
Aug 12, 2024	Oppenheimer	Jay Olson	PT Cut	Outperform	$40→$33
Aug 9, 2024	RBC Capital	Gregory Renza	PT Cut	Sector Perform	$11→$8
Jul 15, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$15

Analyst Ratings News

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

Jefferies analyst Roger Song upgrades Inovio Pharmaceuticals (NASDAQ:INO) from Hold to Buy and raises the price target from $1.8 to $3.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and lowers the price target from $3 to $2.5.

Benzinga Newsdesk

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

Piper Sandler analyst Edward Tenthoff reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Overweight and raises the price target from $5 to $6.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Inovio Pharmaceuticals (NASDAQ:INO) with a Neutral and maintains $3 price target.

Benzinga Newsdesk

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

Inovio Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Inovio Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

Inovio Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

Inovio Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PROPiper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PROHC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PROPiper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PROHC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target

This Wingstop Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

People Also Watch

People Also Watch

PRO
Jefferies Upgrades Inovio Pharmaceuticals to Buy, Raises Price Target to $3

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Lowers Price Target to $4

PRO
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5

PRO
Piper Sandler Reiterates Overweight on Inovio Pharmaceuticals, Raises Price Target to $6

PRO
HC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target